BIOMAT Database Logo BIOMAT Database Logo

Synthesis and structure-activity relationship studies of 3-substituted indolin-2-ones as effective neuroprotective agents. 2008

Michael Balderamos, and Haribabu Ankati, and Shashidhar Kumar Akubathini, and Anish V Patel, and Sukanta Kamila, and Chandrani Mukherjee, and Lulu Wang, and Edward R Biehl, and Santosh R D'Mello
Dept. of Molecular and Cell Biology, University of Texas, Richardson, TX 75083, USA.

Neurodegenerative diseases are a major health problem particularly among the elderly. Drugs to prevent or slow down the death of neurons are urgently needed but are currently unavailable. We previously reported that the c-Raf inhibitor, GW5074 {5-iodo-3-[(3',5'-dibromo-4'-hydroxyphenyl) methylene]-2-indolinone}, is protective in tissue culture and in vivo paradigms of neurodegeneration. However, at doses slightly higher than those at which it is protective, GW5074 displays toxicity when tested in neuronal cultures. We report herein the synthesis, biological evaluation, and structure-activity relationship (SAR) studies of novel 3-substituted indolin-2-one compounds that are highly neuroprotective but lack the toxicity of GW5074. Of the 45 analogs tested in this study, compounds 7, 37, 39, and 45 were found to be the most potent neuroprotective and thus represent promising lead compounds for preclinical development for the treatment of neurodegenerative disorders.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D009410 Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways. Neuron Degeneration,Degeneration, Nerve,Degeneration, Neuron,Degenerations, Nerve,Degenerations, Neuron,Nerve Degenerations,Neuron Degenerations
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D018696 Neuroprotective Agents Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. Neuroprotectant,Neuroprotective Agent,Neuroprotective Drug,Neuroprotectants,Neuroprotective Drugs,Neuroprotective Effect,Neuroprotective Effects,Agent, Neuroprotective,Agents, Neuroprotective,Drug, Neuroprotective,Drugs, Neuroprotective,Effect, Neuroprotective,Effects, Neuroprotective

Related Publications

Michael Balderamos, and Haribabu Ankati, and Shashidhar Kumar Akubathini, and Anish V Patel, and Sukanta Kamila, and Chandrani Mukherjee, and Lulu Wang, and Edward R Biehl, and Santosh R D'Mello
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.
February 2010, Bioorganic & medicinal chemistry,
Michael Balderamos, and Haribabu Ankati, and Shashidhar Kumar Akubathini, and Anish V Patel, and Sukanta Kamila, and Chandrani Mukherjee, and Lulu Wang, and Edward R Biehl, and Santosh R D'Mello
Analogue-based design, synthesis and biological evaluation of 3-substituted-(methylenehydrazono)indolin-2-ones as anticancer agents.
May 2014, European journal of medicinal chemistry,
Michael Balderamos, and Haribabu Ankati, and Shashidhar Kumar Akubathini, and Anish V Patel, and Sukanta Kamila, and Chandrani Mukherjee, and Lulu Wang, and Edward R Biehl, and Santosh R D'Mello
Synthesis and biological evaluation of diversely substituted indolin-2-ones.
November 2008, European journal of medicinal chemistry,
Michael Balderamos, and Haribabu Ankati, and Shashidhar Kumar Akubathini, and Anish V Patel, and Sukanta Kamila, and Chandrani Mukherjee, and Lulu Wang, and Edward R Biehl, and Santosh R D'Mello
Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure-activity relationship analysis.
April 2013, Bioorganic & medicinal chemistry,
Michael Balderamos, and Haribabu Ankati, and Shashidhar Kumar Akubathini, and Anish V Patel, and Sukanta Kamila, and Chandrani Mukherjee, and Lulu Wang, and Edward R Biehl, and Santosh R D'Mello
Solution-phase parallel synthesis of 3,5,6-substituted indolin-2-ones.
January 2007, Journal of combinatorial chemistry,
Michael Balderamos, and Haribabu Ankati, and Shashidhar Kumar Akubathini, and Anish V Patel, and Sukanta Kamila, and Chandrani Mukherjee, and Lulu Wang, and Edward R Biehl, and Santosh R D'Mello
Synthesis, Structure Activity Relationship Studies and Pharmacological Evaluation of 2-Phenyl-3-(Substituted Phenyl)-3H-Quinazolin-4-ones as Serotonin 5-HT(2) Antagonists.
September 2009, Indian journal of pharmaceutical sciences,
Michael Balderamos, and Haribabu Ankati, and Shashidhar Kumar Akubathini, and Anish V Patel, and Sukanta Kamila, and Chandrani Mukherjee, and Lulu Wang, and Edward R Biehl, and Santosh R D'Mello
Synthesis and structure activity relationship study of N-substituted 3,5-diarylidenepiperidin- 4-ones as potential antitumor agents.
February 2014, Anti-cancer agents in medicinal chemistry,
Michael Balderamos, and Haribabu Ankati, and Shashidhar Kumar Akubathini, and Anish V Patel, and Sukanta Kamila, and Chandrani Mukherjee, and Lulu Wang, and Edward R Biehl, and Santosh R D'Mello
Design, synthesis and bio-evaluation of indolin-2-ones as potential antidiabetic agents.
January 2023, Future medicinal chemistry,
Michael Balderamos, and Haribabu Ankati, and Shashidhar Kumar Akubathini, and Anish V Patel, and Sukanta Kamila, and Chandrani Mukherjee, and Lulu Wang, and Edward R Biehl, and Santosh R D'Mello
Synthesis and RET protein kinase inhibitory activity of 3-arylureidobenzylidene-indolin-2-ones.
July 2007, Bioorganic & medicinal chemistry letters,
Michael Balderamos, and Haribabu Ankati, and Shashidhar Kumar Akubathini, and Anish V Patel, and Sukanta Kamila, and Chandrani Mukherjee, and Lulu Wang, and Edward R Biehl, and Santosh R D'Mello
Structure-activity relationship studies of acridones as potential antipsoriatic agents. 2. Synthesis and antiproliferative activity of 10-substituted hydroxy-10H-acridin-9-ones against human keratinocyte growth.
November 2010, European journal of medicinal chemistry,
Copied contents to your clipboard!